VIP

Receptor pharmacology characterised; therapeutic use investigational. Educational only.

VIP is a real endogenous 28-amino-acid neuropeptide with substantial preclinical and mechanistic evidence (PAC1/VPAC receptor signalling, anti-inflammatory action, ADNP upregulation, retinal neuroprotection in BCCAO models). Outside its FDA-approved use as a pharmaceutical aid in specific endocrine testing contexts, robust controlled human outcome trials for nootropic or neuroprotective indications do not exist. Vivre uses VIP under physician supervision for narrowly-scoped indications (CIRS-associated, neuroinflammation) with explicit consent that addresses the preclinical-only evidence class and the ~10× lower potency relative to PACAP noted in the source literature.

Half-life is how long a compound stays at active plasma concentration in your body. Most peptides in this catalogue have short plasma half-lives - they clear from your bloodstream within hours, sometimes minutes. The long-half-life compounds in this catalogue are the approved-class incretins (Tirzepatide, Semaglutide, Retatrutide), which are designed for once-weekly dosing - that's the molecular engineering choice that makes weekly dosing work.

Dosing protocols, administration frequency, and titration schedules are physician-determined at consultation - not published on these public pages. Vivre maintains a separate internal clinical reference for treating physicians.